MX385488B - Lipido cationico. - Google Patents
Lipido cationico.Info
- Publication number
- MX385488B MX385488B MX2018015236A MX2018015236A MX385488B MX 385488 B MX385488 B MX 385488B MX 2018015236 A MX2018015236 A MX 2018015236A MX 2018015236 A MX2018015236 A MX 2018015236A MX 385488 B MX385488 B MX 385488B
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- carbon atoms
- cationic lipid
- formulae
- formula
- Prior art date
Links
- -1 Cationic lipid Chemical class 0.000 title abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000000805 cytoplasm Anatomy 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Indole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La presente invención se refiere a un compuesto representado por la fórmula (la) a continuación o una sal farmacéuticamente aceptable de este: caracterizado porque L1 y L2 representan independientemente un grupo alquileno que tiene de 3 a 10 átomos de carbono ; R1 y R1 representan independiente un grupo alquilo que tiene de 4 a 22 átomos de carbono o un grupo alquenilo que tiene de 4 z 22 átomos de carbono; X1 representa un enlace sencillo o -CO-O-; y el anillo P representa cualquiera de las fórmulas (P-1) a (P-5) a continuación: donde R3 representa un grupo alquilo que tiene de 1 a 3 átomos de carbono.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016125925 | 2016-06-24 | ||
| PCT/JP2017/023051 WO2017222016A1 (ja) | 2016-06-24 | 2017-06-22 | カチオン性脂質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018015236A MX2018015236A (es) | 2019-04-11 |
| MX385488B true MX385488B (es) | 2025-03-18 |
Family
ID=60784078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018015236A MX385488B (es) | 2016-06-24 | 2017-06-22 | Lipido cationico. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10501416B2 (es) |
| EP (1) | EP3476832B1 (es) |
| JP (1) | JP6883034B2 (es) |
| KR (1) | KR102358341B1 (es) |
| CN (1) | CN109311809B (es) |
| AU (1) | AU2017282459B2 (es) |
| BR (1) | BR112018075123A2 (es) |
| ES (1) | ES2948971T3 (es) |
| IL (1) | IL262574B (es) |
| MX (1) | MX385488B (es) |
| RU (1) | RU2740921C2 (es) |
| SG (1) | SG11201808928YA (es) |
| TW (1) | TWI745386B (es) |
| WO (1) | WO2017222016A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019131580A1 (ja) * | 2017-12-27 | 2019-07-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | カチオン性脂質 |
| CN110283223B (zh) * | 2018-03-19 | 2022-01-04 | 广州市锐博生物科技有限公司 | 一种阳离子脂质分子及其在核酸递送中的应用 |
| EP4331681B1 (en) | 2018-08-21 | 2026-06-24 | Kabushiki Kaisha Toshiba | Biodegradable lipids for delivery of active compounds into tumor cells comprising two or more tertiary amino groups |
| US10526603B1 (en) | 2018-10-26 | 2020-01-07 | Eisai R&D Management Co., Ltd. | Double-stranded ribonucleic acid capable of suppressing expression of complement C5 |
| EP4052710A4 (en) | 2019-12-26 | 2024-02-28 | Eisai R&D Management Co., Ltd. | PHARMACEUTICAL COMPOSITION CONTAINING DOUBLE-STRANDED RIBONUCLEIC ACID INHIBITING THE EXPRESSION OF COMPLEMENT C5 |
| JP6918197B2 (ja) * | 2019-12-26 | 2021-08-11 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 脂質複合体を含む医薬組成物及び脂質ナノ粒子を含む医薬組成物 |
| WO2022060871A1 (en) * | 2020-09-15 | 2022-03-24 | Verve Therapeutics, Inc. | Lipid formulations for gene editing |
| WO2022168884A1 (ja) | 2021-02-04 | 2022-08-11 | 塩野義製薬株式会社 | カチオン性脂質 |
| US20250281596A1 (en) * | 2021-09-28 | 2025-09-11 | Seqirus Inc. | Ionizable cationic compound |
| WO2023053017A2 (en) * | 2021-09-28 | 2023-04-06 | Seqirus Inc. | Ionizable cationic compounds for messenger rna delivery |
| JP2025502599A (ja) * | 2021-12-23 | 2025-01-28 | スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド | 脂質化合物及び脂質ナノ粒子組成物 |
| CN114213346B (zh) * | 2022-02-22 | 2022-05-20 | 中国科学院基础医学与肿瘤研究所(筹) | 一种双价可电离脂质化合物、组合物及其应用 |
| AU2024217713A1 (en) * | 2023-02-09 | 2025-08-14 | Seqirus Inc. | Ionizable cationic compound |
| WO2024237214A1 (ja) | 2023-05-12 | 2024-11-21 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 脂質複合体 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009303345B2 (en) | 2008-10-09 | 2015-08-20 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| KR20220038506A (ko) | 2009-06-10 | 2022-03-28 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| EP4481047A3 (en) | 2010-06-03 | 2025-04-16 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| ES2987915T3 (es) | 2010-09-20 | 2024-11-18 | Sirna Therapeutics Inc | Nuevos lípidos catiónicos de bajo peso molecular para el suministro de oligonucleótidos |
| DK2635265T3 (en) | 2010-11-05 | 2018-07-16 | Sirna Therapeutics Inc | New low molecular weight cyclic amine-containing cationic lipids for oligonucleotide delivery |
| AU2012325997C1 (en) | 2011-10-18 | 2018-07-05 | Dicerna Pharmaceuticals, Inc. | Amine cationic lipids and uses thereof |
| DE21212055T1 (de) * | 2011-12-07 | 2022-08-04 | Alnylam Pharmaceuticals, Inc. | Biologisch abbaubare lipide zur freisetzung von wirkstoffen |
| SI2825157T1 (sl) * | 2012-03-16 | 2019-01-31 | Merck Patent Gmbh | Aminokislinski lipidi |
| WO2013158579A1 (en) | 2012-04-19 | 2013-10-24 | Merck Sharp & Dohme Corp. | Novel diester and triester based low molecular weight, biodegradable cationic lipids for oligonucleotide delivery |
| TW201726599A (zh) * | 2012-07-06 | 2017-08-01 | 協和醱酵麒麟有限公司 | 陽離子性脂質 |
| AU2013355258A1 (en) | 2012-12-07 | 2015-06-11 | Alnylam Pharmaceuticals, Inc. | Improved nucleic acid lipid particle formulations |
| TW201534578A (zh) * | 2013-07-08 | 2015-09-16 | Daiichi Sankyo Co Ltd | 新穎脂質 |
| JP2017500865A (ja) | 2013-12-19 | 2017-01-12 | ノバルティス アーゲー | レプチンｍＲＮＡの組成物および製剤 |
| US10426737B2 (en) * | 2013-12-19 | 2019-10-01 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| EP3093283B1 (en) | 2014-01-09 | 2018-12-19 | Eisai R&D Management Co., Ltd. | Cationic lipid |
| JP6641272B2 (ja) * | 2014-06-30 | 2020-02-05 | 協和キリン株式会社 | カチオン性脂質 |
| CA2969664C (en) | 2014-12-26 | 2022-06-21 | Eisai R&D Management Co., Ltd. | Cationic lipid |
-
2017
- 2017-06-22 ES ES17815482T patent/ES2948971T3/es active Active
- 2017-06-22 AU AU2017282459A patent/AU2017282459B2/en not_active Ceased
- 2017-06-22 SG SG11201808928YA patent/SG11201808928YA/en unknown
- 2017-06-22 RU RU2018143237A patent/RU2740921C2/ru active
- 2017-06-22 TW TW106120878A patent/TWI745386B/zh active
- 2017-06-22 MX MX2018015236A patent/MX385488B/es unknown
- 2017-06-22 US US16/307,202 patent/US10501416B2/en active Active
- 2017-06-22 JP JP2018524158A patent/JP6883034B2/ja active Active
- 2017-06-22 CN CN201780035314.7A patent/CN109311809B/zh active Active
- 2017-06-22 WO PCT/JP2017/023051 patent/WO2017222016A1/ja not_active Ceased
- 2017-06-22 KR KR1020187034307A patent/KR102358341B1/ko active Active
- 2017-06-22 BR BR112018075123-5A patent/BR112018075123A2/pt not_active Application Discontinuation
- 2017-06-22 EP EP17815482.9A patent/EP3476832B1/en active Active
-
2018
- 2018-10-24 IL IL262574A patent/IL262574B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018015236A (es) | 2019-04-11 |
| SG11201808928YA (en) | 2018-11-29 |
| IL262574A (en) | 2018-12-31 |
| US10501416B2 (en) | 2019-12-10 |
| TWI745386B (zh) | 2021-11-11 |
| ES2948971T3 (es) | 2023-09-22 |
| CN109311809B (zh) | 2022-04-08 |
| IL262574B (en) | 2021-10-31 |
| KR20190021218A (ko) | 2019-03-05 |
| BR112018075123A2 (pt) | 2019-06-18 |
| EP3476832A4 (en) | 2020-02-19 |
| KR102358341B1 (ko) | 2022-02-07 |
| CN109311809A (zh) | 2019-02-05 |
| JPWO2017222016A1 (ja) | 2019-04-18 |
| TW201803849A (zh) | 2018-02-01 |
| AU2017282459A1 (en) | 2018-11-01 |
| AU2017282459B2 (en) | 2021-05-06 |
| RU2018143237A3 (es) | 2020-07-24 |
| CA3020271A1 (en) | 2017-12-28 |
| WO2017222016A1 (ja) | 2017-12-28 |
| EP3476832B1 (en) | 2023-04-19 |
| US20190218180A1 (en) | 2019-07-18 |
| EP3476832A1 (en) | 2019-05-01 |
| RU2740921C2 (ru) | 2021-01-21 |
| RU2018143237A (ru) | 2020-07-24 |
| JP6883034B2 (ja) | 2021-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808928YA (en) | Cationic lipid | |
| EP4310075A3 (en) | Ionizable cationic lipid for rna delivery | |
| AU2016343803A8 (en) | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
| ZA202206923B (en) | New methylquinazolinone derivatives | |
| EP4458348A3 (en) | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof | |
| JO3430B1 (ar) | مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها | |
| EP4420679A3 (en) | Lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
| MX2020006800A (es) | Lipidos cationicos. | |
| TN2018000395A1 (en) | New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| MX381623B (es) | Composición limpiadora. | |
| TN2018000424A1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| MA38175A1 (fr) | Lactames fusionnés à un aryle et hétéroaryle | |
| MX376833B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| WO2014144545A3 (en) | Substituted benzoxazoles and methods of use thereof | |
| TN2018000410A1 (en) | New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| WO2018121559A8 (zh) | 甘露糖醛二酸的组合物 | |
| MX382122B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| EA201992771A1 (ru) | Ингибитор поверхностного антигена вируса гепатита b | |
| MX2016005993A (es) | Anfifilos biscationicos y triscationicos como agentes antimicrobianos. | |
| CR20170134A (es) | Método para preparar 2´-o-fucosil-lactosa | |
| CR20210181A (es) | Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa | |
| MX2025005209A (es) | Compuestos lipídicos y usos de los mismos | |
| AU2020353055A8 (en) | Antiviral pyrazolopyridinone compounds | |
| TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
| MX386501B (es) | Compuestos terapeuticos y sus metodos de uso |